Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $102.8M rose 40.1% year over year, ahead of the +33.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 26.3% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.
Context
- Operating expenses amounted to 608.6% of revenue in FY2025, up 247.9 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.1% holds above the trailing-twelve-month pace of +33.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 315.39M USD
- Year-over-year change
- +37.2%
- 4-year CAGR
- +28.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 315.39M | +37.2% |
| FY2024 | 2024-12-31 | 229.88M | +69.6% |
| FY2023 | 2023-12-31 | 135.54M | +7.9% |
| FY2022 | 2022-12-31 | 125.61M | +7.2% |
| FY2021 | 2021-12-31 | 117.15M | — |
Operating Expenses vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.6% is the 2nd highest of 10, against a peer median of +10.9%.
- Operating expenses amounts to 662.7% of revenue for OCUL, versus a peer median of 838.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.66B USD | -1.5% | +8.5% | 50.1% | |
| LTM Jun 2026 | $565.37M USD | +32.3% | +17.5% | 92.3% | |
| LTM Mar 2026 | $344.84M USD | +33.6% | +35.9% | 662.7% | |
| LTM Mar 2026 | $287.65M USD | +34.6% | +27.1% | 3777.4% | |
| LTM Sep 2026 | $251.17M USD | +16.0% | -10.8% | — | |
| LTM Apr 2026 | $226.94M USD | -17.3% | +8.3% | 78.2% | |
| LTM Mar 2026 | $170.99M USD | +10.9% | +39.3% | 63.6% | |
| LTM Mar 2026 | $70.72M USD | +14.9% | -10.8% | 1583.9% | |
| LTM Mar 2026 | CHF 69.81M CHF | -10.3% | +34.7% | 13851.6% | |
| LTM Mar 2026 | $59.37M USD | -22.3% | +2.5% | 17821.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $40.84M USD | — | — | — |
| Peer median (excluding OCUL) | — | +10.9% | +8.5% | 838.1% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M |
| Cost of Revenue | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | 39.12M | 46.95M | 53.16M | 58.1M | 45.25M |
| Gross Margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Research & Development | 50.08M | 53.46M | 61.06M | 127.64M | 197.1M |
| Selling, General & Admin | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M |
| Operating Expenses | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| EBITDA | 2.54M | (61.91M) | (66.42M) | (176.14M) | (249.78M) |
| EBITDA Margin | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| Operating Income | (78.04M) | (78.65M) | (82.38M) | (171.78M) | (270.02M) |
| Operating Margin | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| Interest Income | 33K | 798K | 3.98M | 20.28M | 18.36M |
| Interest Expense | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M |
| Other Income / Expenses | 71.48M | 7.62M | 1.65M | (21.73M) | 4.08M |
| Income Before Tax | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Pre-Tax Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Net Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| EPS (Basic) | (1.05) | (1.04) | (1.09) | (1.22) | (1.42) |
| EPS (Diluted) | (0.98) | (0.97) | (1.02) | (1.22) | (1.42) |
| Weighted Avg Shares | 76.39M | 76.88M | 79.83M | 158.27M | 187.24M |
| Weighted Avg Shares (Diluted) | 82.16M | 82.64M | 85.6M | 158.27M | 187.24M |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.